Allogeneic discogenic cell therapy was well tolerated and produced clinically meaningful, statistically significant improvements in low back pain, function, and quality of life by 12 weeks following intradiscal injection
First-of-its-kind precision medicine test to predict a cancer patient’s response to an Immune Checkpoint Inhibitor (ICI)
If approved, PreHevbri will be the only approved 3-antigen hepatitis B vaccine for adults in the E.U.
The bulk drug plants that have already been commissioned include CDA, para amino phenol, atorvastatin, sulfadiazine, oxcarbazepine, levofloxacin, carbidopa and levodopa
Tamper evident caps with incorporated RFID technology offer a significant reduction in RFID implementation costs
The facility is spread across 215000 sq. feet and provides super-speciality care
Boehringer Ingelheim plans to study this novel investigational therapy in patients with progressive fibrosing interstitial lung diseases
Jardiance is the first and only heart failure therapy to demonstrate a statistically significant risk reduction in cardiovascular death or hospitalization for heart failure, regardless of ejection fraction
This new mandate builds upon and strengthens Azelis and Roquette’s global strategic partnership which spans multiple regions and industries.
Fyarro added to NCCN guidelines as the only preferred mTOR inhibitor to treat malignant PEComa
Subscribe To Our Newsletter & Stay Updated
